Christian Clark

Christian Clark requested more granular details on the CKD launch trajectory, a breakdown of Q2 doses between CKD and heart failure, and an update on the company's cash runway and financing options.

Answer

CEO John Tucker clarified that the vast majority of Q2 doses were attributable to heart failure, as the nephrology launch only covered two months of the quarter. He reiterated that nephrologists have been faster adopters than cardiologists. Regarding the balance sheet, Tucker stated the company is 'laser focused' on reaching profitability and has access to an additional $10 million from Perceptive and $25 million in debt if needed.

Christian Clark of Leerink Partners questioned if Xeris plans to generate additional clinical data to strengthen RECORLEV's value proposition, particularly concerning its effect on secondary comorbidities like stubborn diabetes.

Answer

CEO John Shannon affirmed that while there are long-term plans to generate more data, RECORLEV's existing clinical dataset already demonstrates the resolution of comorbidities, such as diabetes, when the underlying elevated cortisol levels are treated. He stated the company will continue to generate more data around this.